Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Biliary Tract Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 162 articles:
HTML format
Text format



Single Articles


    April 2017
  1. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Text format     Abstract available


  2. MIELI-VERGANI G, Vergani D
    The riddle of juvenile sclerosing cholangitis.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29208.
    PubMed     Text format    


  3. DENEAU MR, El-Matary W, Valentino PL, Abdou R, et al
    The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29204.
    PubMed     Text format     Abstract available


    March 2017
  4. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Text format     Abstract available


  5. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Text format     Abstract available


    February 2017
  6. LI H, Zhou ZQ, Yang ZR, Tong DN, et al
    MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Hepatology. 2017 Feb 14. doi: 10.1002/hep.29116.
    PubMed     Text format     Abstract available


  7. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed     Text format    


    January 2017
  8. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Text format     Abstract available


  9. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Text format     Abstract available


  10. SHUAI Z, Wang J, Badamagunta M, Choi J, et al
    The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29059.
    PubMed     Text format     Abstract available


  11. BJORNSSON ES, Jonasson JG
    Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29040.
    PubMed     Text format    


  12. VIVEIROS A, Reiterer M, Schaefer B, Finkenstedt A, et al
    CCBE1 Mutation causing Sclerosing Cholangitis - Expanding the Spectrum of Lymphedema-Cholestasis Syndrome.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29037.
    PubMed     Text format    


  13. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Text format     Abstract available


    December 2016
  14. WANG KS, Tiao G, Bass LM, Hertel PM, et al
    Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29019.
    PubMed     Text format     Abstract available


  15. HAUSSINGER D, Keitel V
    Dual role of the bile acid receptor TGR5 for hepatic lipid metabolism in feast and famine.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29017.
    PubMed     Text format    


  16. QIU YL, Gong JY, Feng JY, Wang RX, et al
    Defects in MYO5B are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29020.
    PubMed     Text format     Abstract available


  17. BRANDI G, De Lorenzo S, Palloni A, Biasco G, et al
    Aspirin for cholangiocarcinoma prevention: new targets to shift the dogma from ascertained risk to possible prevention (Reply to: Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma).
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.28999.
    PubMed     Text format    


  18. TRAUNER M, Fuchs CD, Halilbasic E, Paumgartner G, et al
    New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28991.
    PubMed     Text format     Abstract available


  19. GUPTA R, Gupta J
    Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28994.
    PubMed     Text format    


  20. SAPISOCHIN G, Bruix J
    In response to: Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28993.
    PubMed     Text format    


  21. FAN W, Yang H, Liu T, Wang J, et al
    Prohibitin 1 Suppresses Liver Cancers Tumorigenesis in Mice and Human Hepatocellular and Cholangiocarcinoma cells.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28964.
    PubMed     Text format     Abstract available


  22. BONKOVSKY HL, Kleiner DE, Gu J, Odin JA, et al
    Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28967.
    PubMed     Text format     Abstract available


  23. JANSEN PL, Ghallab A, Vartak N, Reif R, et al
    The ascending pathophysiology of cholestatic liver disease.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28965.
    PubMed     Text format     Abstract available


    November 2016
  24. DE VRIES EM, de Krijger M, Farkkila M, Arola J, et al
    Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28963.
    PubMed     Text format     Abstract available


  25. MOHANTY SK, Donnelly B, Lobeck I, Walther A, et al
    The SRL peptide of Rhesus Rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.
    Hepatology. 2016 Nov 17. doi: 10.1002/hep.28947.
    PubMed     Text format     Abstract available


  26. SAMUR S, Klebanoff M, Banken R, Pratt DS, et al
    Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28932.
    PubMed     Text format     Abstract available


  27. GRADILONE SA
    Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28925.
    PubMed     Text format    


  28. ALTAII H, Al-Kindi SG, Oliveira GH, Yaqoob Z, et al
    Aspirin use and risk of cholangiocarcinoma: External validation with big data.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28920.
    PubMed     Text format    


  29. YAN S, Tang J, Zhang Y, Wang Y, et al
    Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3-mediated hepatocyte nuclear receptor 4alpha/cholesterol 7alpha-hydroxylase pathway in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28928.
    PubMed     Text format     Abstract available


    October 2016
  30. DESAI M, Mathur B, Eblimit Z, Vasquez H, et al
    Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28890.
    PubMed     Text format     Abstract available


  31. ZHANG L, Yang Z, Trottier J, Barbier O, et al
    LncRNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate Shp mRNA decay.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28882.
    PubMed     Text format     Abstract available


    September 2016
  32. DAHLQVIST G, Gaouar F, Carrat F, Meurisse S, et al
    Large-scale characterization study of patients with antimitochondrial antibodies but non-established primary biliary cholangitis.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28859.
    PubMed     Text format     Abstract available


  33. LAGES CS, Simmons J, Maddox A, Jones K, et al
    The dendritic cell-Th17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28851.
    PubMed     Text format     Abstract available


  34. KULKARNI SR, Soroka CJ, Hagey LR, Boyer JL, et al
    Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid fed mouse model of cholestasis.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28826.
    PubMed     Text format     Abstract available


  35. MCDANIEL K, Meng F, Wu N, Sato K, et al
    Forkhead box A2 regulated biliary heterogeneity and senescence during cholestatic liver injury.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28831.
    PubMed     Text format     Abstract available


  36. KAMINSKY P, Preiss J, Sasatomi E, Gerber DA, et al
    Biliary Adenofibroma: A Rare Hepatic Lesion with Malignant Features.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28818.
    PubMed     Text format    


  37. FIOROTTO R, Villani A, Kourtidis A, Scirpo R, et al
    CFTR controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28817.
    PubMed     Text format     Abstract available


    August 2016
  38. OKABE H, Yang J, Sylakowski K, Yovchev M, et al
    Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28774.
    PubMed     Text format     Abstract available


  39. WANG J, Xie C, Pan S, Liang Y, et al
    NDRG2 Inhibits Human Cholangiocarcinoma Progression and Is Regulated by LIF/MicroRNA-181c Negative feedback Pathway.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28781.
    PubMed     Text format     Abstract available


  40. GONZALES E, Taylor SA, Davit-Spraul A, Thebaut A, et al
    MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28779.
    PubMed     Text format     Abstract available


  41. SAPISOCHIN G, Facciuto M, Rubbia-Brandt L, Marti J, et al
    Liver transplantation for "very early" intrahepatic cholangiocarcinoma. international retrospective study supporting a prospective assessment.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28744.
    PubMed     Text format     Abstract available


    July 2016
  42. LI L, Piontek K, Ishida M, Fausther M, et al
    Extracellular vesicles carry miR-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28735.
    PubMed     Text format     Abstract available


  43. MARINELLI RA, Marrone J
    Aquaporin Gene Therapy for Cholestasis.
    Hepatology. 2016 Jul 26. doi: 10.1002/hep.28734.
    PubMed     Text format    


  44. KOPPE C, Verheugd P, Gautheron J, Reisinger F, et al
    IKKalpha/beta control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator RIPK1.
    Hepatology. 2016 Jul 11. doi: 10.1002/hep.28723.
    PubMed     Text format     Abstract available


  45. VERGANI D, Mieli-Vergani G
    Mouse model of primary biliary cholangitis with a striking female predominance: A new powerful research tool.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28718.
    PubMed     Text format    


    June 2016
  46. XU Y, Li F, Zalzala M, Xu J, et al
    FXR Activation Increases Reverse Cholesterol Transport by Modulating Bile Acid Composition and Cholesterol Absorption.
    Hepatology. 2016 Jun 30. doi: 10.1002/hep.28712.
    PubMed     Text format     Abstract available


  47. ARAB JP, Karpen SJ, Dawson PA, Arrese M, et al
    Bile acids & nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
    Hepatology. 2016 Jun 30. doi: 10.1002/hep.28709.
    PubMed     Text format     Abstract available


  48. DONEPUDI AC, Boehme S, Li F, Chiang JY, et al
    G protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28707.
    PubMed     Text format     Abstract available


  49. JONES H, Hargrove L, Kennedy L, Meng F, et al
    Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2-/- mice.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28704.
    PubMed     Text format     Abstract available


  50. WALESKY C, Goessling W
    Nature and Nurture - Environmental Toxins and Biliary Atresia.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28701.
    PubMed     Text format    


  51. ROSENCRANTZ RA, Huang T, Sonke PY, Tewari D, et al
    Autoimmune Sclerosing Cholangitis: An Atypical Association with Kawasaki Disease.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28694.
    PubMed     Text format    


  52. WAGNER M, Fickert P, Zollner G
    Secretin and cholestasis, two sides of a coin.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28687.
    PubMed     Text format    


  53. BESNARD A, Gautherot J, Julien B, Tebbi A, et al
    The P2X4 purinergic receptor impacts liver regeneration after partial hepatectomy in mice through the regulation of biliary homeostasis.
    Hepatology. 2016 Jun 15. doi: 10.1002/hep.28675.
    PubMed     Text format     Abstract available


    May 2016
  54. HAPPERTS S, Foucault A, Billiard JS, Nguyen B, et al
    Combined hepatocellular-cholangiocarcinoma in a patient with Abernethy malformation and Tetralogy of Fallot - A case report.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28656.
    PubMed     Text format    


  55. GROEN AK
    Unexpected cholesterol gallstones.
    Hepatology. 2016 May 17. doi: 10.1002/hep.28646.
    PubMed     Text format    


  56. HOFMANN AF
    Let the Bile Flow! 1.0.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28633.
    PubMed     Text format    


  57. BAE HR, Leung PS, Tsuneyama K, Valencia JC, et al
    Chronic Expression of Interferon Gamma Leads to Murine Autoimmune Cholangitis with a Female Predominance.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28641.
    PubMed     Text format     Abstract available


  58. DUFFY AG, Makarova-Rusher OV, Greten TF
    The case for immune-based approaches in biliary tract carcinoma.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28635.
    PubMed     Text format     Abstract available


  59. BEZERRA JA
    MDR3 mutation analysis: A step closer to precision medicine.
    Hepatology. 2016;63:1421-3.
    PubMed     Text format    


  60. LIASKOU E, Klemsdal Henriksen EK, Holm K, Kaveh F, et al
    High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.
    Hepatology. 2016;63:1608-19.
    PubMed     Text format     Abstract available


    April 2016
  61. TRADTRANTIP L, Verkman AS
    Aquaporin gene therapy for disorders of cholestasis?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28623.
    PubMed     Text format    


  62. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Text format     Abstract available


  63. BAGANTE F, Clark Gamblin T, Pawlik TM
    Cholangiocarcinoma Risk Factors and the Potential Role of Aspirin.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28613.
    PubMed     Text format    


  64. BERASAIN C, Fernandez-Barrena MG, Avila MA
    New molecular interactions of c-Myc in cholangiocarcinoma may open new therapeutic opportunities.
    Hepatology. 2016 Apr 21. doi: 10.1002/hep.28607.
    PubMed     Text format    


  65. REID LM
    Stem/progenitor cells and reprogramming (plasticity) mechanisms in liver, biliary tree and pancreas.
    Hepatology. 2016 Apr 21. doi: 10.1002/hep.28606.
    PubMed     Text format     Abstract available


  66. ZHAO X, Lorent K, Wilkins B, Marchione DM, et al
    Glutathione antioxidant pathway activity and reserve determine toxicity and specificity of the biliary toxin biliatresone in zebrafish.
    Hepatology. 2016 Apr 21. doi: 10.1002/hep.28603.
    PubMed     Text format     Abstract available


  67. WAISBOURD-ZINMAN O, Koh H, Tsai S, Lavrut PM, et al
    The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis via decreased glutathione and SOX17.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28599.
    PubMed     Text format     Abstract available


  68. TABIBIAN JH, Abu Dayyeh BK, Gores GJ, Levy MJ, et al
    A novel, minimally invasive technique for management of peristomal varices.
    Hepatology. 2016;63:1398-400.
    PubMed     Text format    


    March 2016
  69. DOORENSPLEET ME, Hubers LM, Culver EL, Maillette de Buy Wenniger LJ, et al
    IgG4+ B-Cell Receptor Clones Distinguish IgG4-Related Disease from Primary Sclerosing Cholangitis and Biliary/Pancreatic Malignancies.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28568.
    PubMed     Text format     Abstract available


  70. WANG HH, Li X, Patel SB, Wang DQ, et al
    Evidence that the ABCG5/G8-independent pathway plays a determinant role in cholesterol gallstone formation in mice.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28570.
    PubMed     Text format     Abstract available


  71. MARRONE J, Soria LR, Danielli M, Lehmann GL, et al
    Hepatic Gene Transfer of Human Aquaporin-1 Improves Bile Salt Secretory Failure in Rats with Estrogen-Induced Cholestasis.
    Hepatology. 2016 Mar 21. doi: 10.1002/hep.28564.
    PubMed     Text format     Abstract available


  72. CHANG JC, Go S, de Waart DR, Munoz-Garrido P, et al
    Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28550.
    PubMed     Text format     Abstract available


  73. ALVARO D, Gaudio E
    Biliary tree stem cell subpopulations.
    Hepatology. 2016 Mar 12. doi: 10.1002/hep.28546.
    PubMed     Text format    


  74. FRIEDRICH K, Smit M, Brune M, Giese T, et al
    CD14 is associated with biliary stricture formation.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28543.
    PubMed     Text format     Abstract available


  75. YANG H, Liu T, Wang J, Li TW, et al
    Deregulated methionine adenosyltransferase alpha1, c-myc and maf proteins interplay promotes cholangiocarcinoma growth in mice and humans.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28541.
    PubMed     Text format     Abstract available


  76. CHOI J, Ghoz HM, Peeraphatdit T, Baichoo E, et al
    Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma.
    Hepatology. 2016 Mar 3. doi: 10.1002/hep.28529.
    PubMed     Text format     Abstract available


    February 2016
  77. ANANTHANARAYANAN M
    A novel long non-coding RNA (lncRNA) regulating Cholesterol and Bile acid homeostasis: A new kid on the block and a potential Therapeutic Target?
    Hepatology. 2016 Feb 29. doi: 10.1002/hep.28525.
    PubMed     Text format    


  78. DE WAART DR, Naik J, Utsunomiya KS, Duijst S, et al
    ATP11C targets basolateral bile salt transporter proteins in mouse central hepatocytes.
    Hepatology. 2016 Feb 29. doi: 10.1002/hep.28522.
    PubMed     Text format     Abstract available


  79. TANIMIZU N, Kaneko K, Itoh T, Ichinohe N, et al
    Intrahepatic bile ducts are developed through formation of homogeneous continuous luminal network and its dynamic rearrangement.
    Hepatology. 2016 Feb 29. doi: 10.1002/hep.28521.
    PubMed     Text format     Abstract available


  80. LI L, Che L, Tharp KM, Park HM, et al
    Differential Requirement for de novo Lipogenesis in Cholangiocarcinoma and Hepatocellular Carcinoma of Mice and Humans.
    Hepatology. 2016 Feb 22. doi: 10.1002/hep.28508.
    PubMed     Text format     Abstract available


  81. GUAN L, Zhang L, Gong Z, Hou X, et al
    FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance via Keap1-Nrf2 signaling.
    Hepatology. 2016 Feb 9. doi: 10.1002/hep.28496.
    PubMed     Text format     Abstract available


  82. WU W, Patel A, Kyostila K, Lohi H, et al
    Genome-wide Association Study in Mice Identifies Loci Affecting Liver-related Phenotypes Including Sel1l Influencing Serum Bile Acids.
    Hepatology. 2016 Feb 9. doi: 10.1002/hep.28495.
    PubMed     Text format     Abstract available


  83. OIKAWA T
    Cancer Stem Cells and Their Cellular Origins in Primary Liver and Biliary Tract Cancers.
    Hepatology. 2016 Feb 5. doi: 10.1002/hep.28485.
    PubMed     Text format     Abstract available


  84. HUPPERT SS
    A faithful JAGGED1 haploinsufficiency mouse model of arteriohepatic dysplasia (Alagille syndrome) after all.
    Hepatology. 2016;63:365-7.
    PubMed     Text format    


    January 2016
  85. TRIVEDI PJ, Weston CJ, Webb GJ, Newsome PN, et al
    Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-) ) knockout mice is strain specific.
    Hepatology. 2016;63:346.
    PubMed     Text format    


  86. KRONES E, Erwa W, Trauner M, Fickert P, et al
    Reply.
    Hepatology. 2016;63:346-7.
    PubMed     Text format    


    December 2015
  87. RIZVI S, Gores GJ
    Cholangiocarcinoma (CCA).
    Hepatology. 2015 Dec 15. doi: 10.1002/hep.28401.
    PubMed     Text format    


  88. LOCATELLI L, Cadamuro M, Spirli C, Fiorotto R, et al
    Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28382.
    PubMed     Text format     Abstract available


  89. EKSTEEN B
    Predicting risk in Primary Biliary Cholangitis.
    Hepatology. 2015 Dec 5. doi: 10.1002/hep.28377.
    PubMed     Text format    


    November 2015
  90. VARTAK N, Damle-Vartak A, Richter B, Dirsch O, et al
    Cholestasis-induced adaptive remodeling of interlobular bile ducts.
    Hepatology. 2015 Nov 26. doi: 10.1002/hep.28373.
    PubMed     Text format     Abstract available


  91. DAWSON PA
    Toxic Bile and Sclerosing Cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28363.
    PubMed     Text format    


  92. REYES H
    Sulfated progesterone metabolites in the pathogenesis of intrahepatic cholestasis of pregnancy: Another loop in the ascending spiral of medical knowledge.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28365.
    PubMed     Text format    


  93. JANSEN PL, Schaap FG
    Pandora's box opens for cholestatic liver disease.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28364.
    PubMed     Text format    


  94. HIRSCHFIELD GM, Gershwin ME, Strauss R, Mayo MJ, et al
    Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to Ursodeoxycholic Acid: a proof-of-concept study.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28359.
    PubMed     Text format     Abstract available


  95. LANZONI G, Cardinale V, Carpino G
    The hepatic, biliary and pancreatic network of stem/progenitor cells niches in humans: A new reference frame for disease and regeneration.
    Hepatology. 2015 Nov 2. doi: 10.1002/hep.28326.
    PubMed     Text format     Abstract available


  96. KUMTA NA, DeRoche K, Kahaleh M
    Temoporfin photodynamic therapy in advanced hilar ductal carcinoma: A promising endoscopic modality.
    Hepatology. 2015;62:1342-3.
    PubMed     Text format    


    October 2015
  97. YOKOMORI H, Yamazaki H, Oda M
    Freshwater clam extract supplement induced acute cholestasis.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28320.
    PubMed     Text format    


  98. STINDT J, Kluge S, Droge C, Keitel V, et al
    Bile Salt Export Pump-reactive Antibodies Form a Polyclonal, Multi-inhibitory Response in Antibody-induced BSEP Deficiency.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28311.
    PubMed     Text format     Abstract available


  99. LI Q, Kresge C, Bugde A, Lamphere M, et al
    Regulation of mechanosensitive biliary epithelial transport by the Epithelial Na Channel, ENaC.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28301.
    PubMed     Text format     Abstract available


  100. DELAUNAY JL, Durand-Schneider AM, Dossier C, Falguieres T, et al
    A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28300.
    PubMed     Text format     Abstract available


  101. REYES H
    What have we learned about Intrahepatic Cholestasis of Pregnancy?
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28295.
    PubMed     Text format    


  102. PENG ZW, Ikenaga N, Liu SB, Sverdlov DY, et al
    Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis and tumorigenesis.
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28274.
    PubMed     Text format     Abstract available


  103. LI Z, Feng J, Sun X
    Hypomethylation and hypohydroxymethylation of DNA in hepatocellular carcinoma and cholangiocarcinoma.
    Hepatology. 2015 Oct 5. doi: 10.1002/hep.28272.
    PubMed     Text format    


  104. ABU-HAYYEH S, Ovadia C, Lieu T, Jensen DD, et al
    Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum.
    Hepatology. 2015 Oct 1. doi: 10.1002/hep.28265.
    PubMed     Text format     Abstract available


    September 2015
  105. ZHOU M, Marc Learned R, Rossi SJ, DePaoli AM, et al
    Engineered FGF19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28257.
    PubMed     Text format     Abstract available


  106. PONSIOEN CY, Chapman RW, Chazouilleres O, Hirschfield GM, et al
    Surrogate endpoints for clinical trials in primary sclerosing cholangitis; review and results from an International PSC Study Group consensus process.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28256.
    PubMed     Text format     Abstract available


  107. KOHLI R, Setchell KD
    Let the Bile Flow!
    Hepatology. 2015 Sep 22. doi: 10.1002/hep.28244.
    PubMed     Text format    


  108. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    Hepatology. 2015 Sep 15. doi: 10.1002/hep.28140.
    PubMed     Text format    


  109. GIOVANNONI R, Villanueva A
    Circulating tumor cells and cholangiocarcinoma.
    Hepatology. 2015 Sep 11. doi: 10.1002/hep.28152.
    PubMed     Text format    


  110. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
    Hepatology. 2015 Sep 4. doi: 10.1002/hep.28149.
    PubMed     Text format     Abstract available


  111. LEDERER A, Herrmann P, Seehofer D, Dietel M, et al
    Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients.
    Hepatology. 2015;62:841-50.
    PubMed     Text format     Abstract available


    August 2015
  112. SPIRLI C, Villani A, Mariotti V, Fabris L, et al
    Post-Translational Regulation of Polycystin-2 Protein Expression as a Novel Mechanism of Cholangiocyte Reaction and Repair from Biliary Damage.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28138.
    PubMed     Text format     Abstract available


  113. MARSCHALL HU, Backhed F
    Could gut microbiota protect against sclerosing cholangitis?
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28135.
    PubMed     Text format    


  114. TRIVEDI PJ, Corpechot C, Pares A, Hirschfield GM, et al
    Risk Stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.
    Hepatology. 2015 Aug 20. doi: 10.1002/hep.28128.
    PubMed     Text format     Abstract available


  115. SHIMODA S, Hisamoto S, Harada K, Iwasaka S, et al
    Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28122.
    PubMed     Text format     Abstract available


  116. THAKURDAS SM, Lopez MF, Kakuda S, Fernandez-Valdivia R, et al
    Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi).
    Hepatology. 2015 Aug 1. doi: 10.1002/hep.28024.
    PubMed     Text format     Abstract available


  117. THOMPSON RJ, Bull LN
    Treating genetic disease: Expanding the options.
    Hepatology. 2015;62:349-51.
    PubMed     Text format    


    July 2015
  118. CARBONE M, Sharp SJ, Flack S, Paximadas D, et al
    The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28017.
    PubMed     Text format     Abstract available


  119. SCIRPO R, Fiorotto R, Villani A, Amenduni M, et al
    Stimulation of nuclear receptor PPAR-gamma limits NF-kB-dependent inflammation in mouse cystic fibrosis biliary epithelium.
    Hepatology. 2015 Jul 21. doi: 10.1002/hep.28000.
    PubMed     Text format     Abstract available


  120. MARTI P, Stein C, Blumer T, Abraham Y, et al
    YAP promotes proliferation, chemoresistance and angiogenesis in human cholangiocarcinoma via TEAD transcription factors.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27992.
    PubMed     Text format     Abstract available


  121. MIETHKE AG, Zhang W, Simmons J, Taylor A, et al
    Pharmacological inhibition of ASBT changes bile composition and blocks progression of sclerosing cholangitis in mdr2 knockout mice.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27973.
    PubMed     Text format     Abstract available


  122. LI XY, Bai MJ, Chen LJ, Xu JL, et al
    Issue in statistical strategy in case-control study.
    Hepatology. 2015;62:320.
    PubMed     Text format    


  123. ALEKSANDROVA K, Pischon T
    Reply.
    Hepatology. 2015;62:320-1.
    PubMed     Text format    


    June 2015
  124. CHIANG JY
    Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27964.
    PubMed     Text format    


  125. CARULLI L, Gabbi C, Bertolotti M
    Bile acids and non-alcoholic fatty liver disease: An intriguing relationship.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27963.
    PubMed     Text format    


  126. HYLEMON P, Nagahashi M, Takabe K, Zhou H, et al
    Sphingosine-1-phosphate receptor 2 and conjugated bile acids: Key players in hepatic lipid metabolism.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27961.
    PubMed     Text format    


  127. BARBIER-TORRES L, Beraza N, Fernandez-Tussy P, Lopitz-Otsoa F, et al
    Histone Deacetylase 4 promotes cholestatic liver injury in the absence of Prohibitin-1.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27959.
    PubMed     Text format     Abstract available


  128. LI M, Mennone A, Soroka CJ, Hagey LR, et al
    NHERF-1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27956.
    PubMed     Text format     Abstract available


  129. YANG JD, Campion MB, Liu MC, Chaiteerakij R, et al
    Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma.
    Hepatology. 2015 Jun 19. doi: 10.1002/hep.27944.
    PubMed     Text format     Abstract available


  130. TABIBIAN JH, O'Hara SP, Trussoni CE, Tietz PS, et al
    Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.
    Hepatology. 2015 Jun 4. doi: 10.1002/hep.27927.
    PubMed     Text format     Abstract available


  131. BERGASA NV
    The pruritus of cholestasis: facts.
    Hepatology. 2015;61:2114.
    PubMed     Text format    


    May 2015
  132. WAGNER A, Denzer UW, Neureiter D, Kiesslich T, et al
    Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study.
    Hepatology. 2015 May 20. doi: 10.1002/hep.27905.
    PubMed     Text format     Abstract available


  133. KUMAR S
    Cholestatic Liver Injury secondary to Artemisinin.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27900.
    PubMed     Text format    


  134. LIBERAL R, Grant CR, Holder BS, Cardone J, et al
    In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.
    Hepatology. 2015 May 8. doi: 10.1002/hep.27884.
    PubMed     Text format     Abstract available


    April 2015
  135. SEBODE M, Schramm C
    NKT cells: Novel players in biliary disease?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27862.
    PubMed     Text format    


  136. SCHRUMPF E, Tan C, Karlsen TH, Sponheim J, et al
    The Biliary Epithelium Presents Antigens to and Activates Natural Killer T Cells.
    Hepatology. 2015 Apr 8. doi: 10.1002/hep.27840.
    PubMed     Text format     Abstract available


  137. VARMA S, Revencu N, Stephenne X, Scheers I, et al
    Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis Type 2.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27834.
    PubMed     Text format     Abstract available


  138. VESTERHUS M, Hov JR, Holm A, Schrumpf E, et al
    Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
    Hepatology. 2015 Apr 1. doi: 10.1002/hep.27825.
    PubMed     Text format     Abstract available


  139. UDALI S, Guarini P, Moruzzi S, Ruzzenente A, et al
    Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate.
    Hepatology. 2015 Apr 1. doi: 10.1002/hep.27823.
    PubMed     Text format     Abstract available


  140. YANG Z, Zhang X, Roberts RO, Roberts LR, et al
    Metformin does not improve survival of cholangiocarcinoma in persons with diabetes.
    Hepatology. 2015 Apr 1. doi: 10.1002/hep.27821.
    PubMed     Text format    


  141. SCHRAMM C, Wahl I, Lohse AW
    Reply.
    Hepatology. 2015;61:1435.
    PubMed     Text format    


    March 2015
  142. SUCHY FJ, Ananthanarayanan M
    Bile acid hepatotoxicity: Epigenetics comes to the rescue.
    Hepatology. 2015 Mar 25. doi: 10.1002/hep.27807.
    PubMed     Text format    


  143. KOSTERS A, Dawson PA
    The Na -taurocholate cotransporting polypeptide (Ntcp) knockout mouse: A new tool for study of bile acids and Hepatitis B virus biology.
    Hepatology. 2015 Mar 12. doi: 10.1002/hep.27780.
    PubMed     Text format    


  144. LI L, Selaru FM
    Reply: To PMID 21858175.
    Hepatology. 2015;61:1095-6.
    PubMed     Text format    


    February 2015
  145. GONZALES E, Grosse B, Schuller B, Davit-Spraul A, et al
    Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate.
    Hepatology. 2015 Feb 26. doi: 10.1002/hep.27767.
    PubMed     Text format     Abstract available


  146. GHONEM NS, Assis DN, Boyer JL
    On fibrates and cholestasis: A review.
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27744.
    PubMed     Text format     Abstract available


  147. BOYER JL
    The origins of hepatobiliary and gastrointestinal physiology.
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27737.
    PubMed     Text format    


  148. MOURYA R, Bessho K, Shivakumar P, Bezerra JA, et al
    Reply: To PMID 24493287.
    Hepatology. 2015;61:732-3.
    PubMed     Text format    


    January 2015
  149. LI Y, Wang W, Tang L, He X, et al
    CXCL13 promotes intrahepatic CXCR5 lymphocyte homing and aberrant B cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Jan 27. doi: 10.1002/hep.27725.
    PubMed     Text format     Abstract available


  150. POUPON R
    Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation.
    Hepatology. 2015 Jan 20. doi: 10.1002/hep.27715.
    PubMed     Text format     Abstract available


  151. ANDRESEN K, Boberg KM, Vedeld HM, Honne H, et al
    Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27707.
    PubMed     Text format     Abstract available


  152. SLIJEPCEVIC D, Kaufman C, Wichers CG, Gilglioni EH, et al
    Impaired uptake of conjugated bile acids and Hepatitis B Virus preS1-binding in Na -taurocholate cotransporting polypeptide knockout mice.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27694.
    PubMed     Text format     Abstract available


  153. KANEKO K, Kamimoto K, Miyajima A, Itoh T, et al
    Adaptive remodeling of the biliary architecture underlies liver homeostasis.
    Hepatology. 2015 Jan 8. doi: 10.1002/hep.27685.
    PubMed     Text format     Abstract available


  154. YAMADA D, Rizvi S, Razumilava N, Bronk SF, et al
    IL-33 facilitates oncogene induced cholangiocarcinoma in mice by an IL-6 sensitive mechanism.
    Hepatology. 2015 Jan 7. doi: 10.1002/hep.27687.
    PubMed     Text format     Abstract available


    December 2014
  155. KIM Y, Fang S, Byun S, Seok S, et al
    FXR-induced lysine-specific histone demethylase, LSD1, reduces hepatic bile acid levels and protects the liver against bile acid toxicity.
    Hepatology. 2014 Dec 24. doi: 10.1002/hep.27677.
    PubMed     Text format     Abstract available


  156. FOUASSIER L, Fiorotto R
    Ezrin finds its groove in cholangiocytes.
    Hepatology. 2014 Dec 24. doi: 10.1002/hep.27675.
    PubMed     Text format    


  157. MIAMEN AG, Gustafson MP, Roberts LR
    Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers.
    Hepatology. 2014;60:2121-4.
    PubMed     Text format    


  158. ABU-HAYYEH S, Williamson C
    Estradiol, farnesoid X receptor, and altered metabolism in pregnancy.
    Hepatology. 2014;60:1815-7.
    PubMed     Text format    


    November 2014
  159. KRONES E, Erwa W, Trauner M, Fickert P, et al
    Serum alkaline phosphatase levels accurately reflect cholestasis in mice.
    Hepatology. 2014 Nov 25. doi: 10.1002/hep.27622.
    PubMed     Text format    


  160. CHIANG JY
    Sphingosine-1-phosphate receptor 2: A novel bile acid receptor and regulator of hepatic lipid metabolism?
    Hepatology. 2014 Nov 22. doi: 10.1002/hep.27616.
    PubMed     Text format    


  161. DORMAN C, Wong M, Khan A
    Cholestatic hepatitis from prolonged kratom use: A case report.
    Hepatology. 2014 Nov 22. doi: 10.1002/hep.27612.
    PubMed     Text format    


  162. NAGAHASHI M, Takabe K, Liu R, Peng K, et al
    Conjugated Bile Acid Activated S1P Receptor 2 Is a Key Regulator of Sphingosine Kinase 2 and Hepatic Gene Expression.
    Hepatology. 2014 Nov 1. doi: 10.1002/hep.27592.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: